Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy

Photodynamic therapy (PDT) is a special form of phototherapy in which oxygen is needed, in addition to light and a drug called a photosensitiser (PS), to create cytotoxic species that can destroy cancer cells and various pathogens. PDT is often used in combination with other antitumor and antimicrob...

Full description

Bibliographic Details
Main Authors: Martina Mušković, Rafaela Pokrajac, Nela Malatesti
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/16/4/613
_version_ 1827744053298462720
author Martina Mušković
Rafaela Pokrajac
Nela Malatesti
author_facet Martina Mušković
Rafaela Pokrajac
Nela Malatesti
author_sort Martina Mušković
collection DOAJ
description Photodynamic therapy (PDT) is a special form of phototherapy in which oxygen is needed, in addition to light and a drug called a photosensitiser (PS), to create cytotoxic species that can destroy cancer cells and various pathogens. PDT is often used in combination with other antitumor and antimicrobial therapies to sensitise cells to other agents, minimise the risk of resistance and improve overall outcomes. Furthermore, the aim of combining two photosensitising agents in PDT is to overcome the shortcomings of the monotherapeutic approach and the limitations of individual agents, as well as to achieve synergistic or additive effects, which allows the administration of PSs in lower concentrations, consequently reducing dark toxicity and preventing skin photosensitivity. The most common strategies in anticancer PDT use two PSs to combine the targeting of different organelles and cell-death mechanisms and, in addition to cancer cells, simultaneously target tumour vasculature and induce immune responses. The use of PDT with upconversion nanoparticles is a promising approach to the treatment of deep tissues and the goal of using two PSs is to improve drug loading and singlet oxygen production. In antimicrobial PDT, two PSs are often combined to generate various reactive oxygen species through both Type I and Type II processes.
first_indexed 2024-03-11T04:38:30Z
format Article
id doaj.art-a3b44436283a48c791e42a8c3aa7e941
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-03-11T04:38:30Z
publishDate 2023-04-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-a3b44436283a48c791e42a8c3aa7e9412023-11-17T20:51:24ZengMDPI AGPharmaceuticals1424-82472023-04-0116461310.3390/ph16040613Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic TherapyMartina Mušković0Rafaela Pokrajac1Nela Malatesti2Department of Biotechnology, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, CroatiaDepartment of Biotechnology, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, CroatiaDepartment of Biotechnology, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, CroatiaPhotodynamic therapy (PDT) is a special form of phototherapy in which oxygen is needed, in addition to light and a drug called a photosensitiser (PS), to create cytotoxic species that can destroy cancer cells and various pathogens. PDT is often used in combination with other antitumor and antimicrobial therapies to sensitise cells to other agents, minimise the risk of resistance and improve overall outcomes. Furthermore, the aim of combining two photosensitising agents in PDT is to overcome the shortcomings of the monotherapeutic approach and the limitations of individual agents, as well as to achieve synergistic or additive effects, which allows the administration of PSs in lower concentrations, consequently reducing dark toxicity and preventing skin photosensitivity. The most common strategies in anticancer PDT use two PSs to combine the targeting of different organelles and cell-death mechanisms and, in addition to cancer cells, simultaneously target tumour vasculature and induce immune responses. The use of PDT with upconversion nanoparticles is a promising approach to the treatment of deep tissues and the goal of using two PSs is to improve drug loading and singlet oxygen production. In antimicrobial PDT, two PSs are often combined to generate various reactive oxygen species through both Type I and Type II processes.https://www.mdpi.com/1424-8247/16/4/613photosensitiseranticancer photodynamic treatmentantimicrobial photodynamic treatmentupconversion nanoparticles
spellingShingle Martina Mušković
Rafaela Pokrajac
Nela Malatesti
Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
Pharmaceuticals
photosensitiser
anticancer photodynamic treatment
antimicrobial photodynamic treatment
upconversion nanoparticles
title Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
title_full Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
title_fullStr Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
title_full_unstemmed Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
title_short Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy
title_sort combination of two photosensitisers in anticancer antimicrobial and upconversion photodynamic therapy
topic photosensitiser
anticancer photodynamic treatment
antimicrobial photodynamic treatment
upconversion nanoparticles
url https://www.mdpi.com/1424-8247/16/4/613
work_keys_str_mv AT martinamuskovic combinationoftwophotosensitisersinanticancerantimicrobialandupconversionphotodynamictherapy
AT rafaelapokrajac combinationoftwophotosensitisersinanticancerantimicrobialandupconversionphotodynamictherapy
AT nelamalatesti combinationoftwophotosensitisersinanticancerantimicrobialandupconversionphotodynamictherapy